Dr. Fabian Mohr

Dr. Fabian Mohr

Dr. Fabian Mohr holds a PhD in molecular medicine and supports the HTGF Life Science practice as investment manager. Before joining HTGF, Fabian was a project lead in strategy consulting for product innovation, data driven business models, M&A and evaluation of new technology use-cases in the Life Science and Medical Technology industry.

Contact

E-Mail:
f.mohr@htgf.de
Telefon:
+49 – (0)228 – 82300 – 181

Portfolio

Events

13. July 2021
Pitch- and Network-Event | PALATINA BA Rhein-Neckar e.V.
The purpose of the association is to promote a regional business angels culture by building a business angels network. Founders and members want to raise awareness that the promotion of innovative and young companies and business ideas is essential for the economic and intellectual future. Since September 2020, PALATINA BA Rhein-Neckar e.V. has held 8 pitch events and presented about 40 startups. The next online event (via ZOOM) is: DI, 13.7.2021, start 18:00. HTGF presentation will be made by o
 

Posts & mentions

2. March 2021

Newly founded biotech company ActiTrexx receives funding of € 3.5 million to develop cell therapy against transplant rejection

ActiTrexx GmbH, a new biotech spin-off from the University Medical Center Mainz, Germany, has successfully closed its Series A financing. A consortium led by LBBW Venture Capital GmbH with participation from MediVentures GmbH, High-Tech Gründerfonds (HTGF) and Investitions- und Strukturbank Rheinland-Pfalz (ISB) invested a total of € 3.5 million. ActiTrexx develops ATreg, activated regulatory T cells (Tregs), which are stimulated using a proprietary process, to prevent rejection r
 
12. November 2020

Synendos Therapeutics Raises CHF 20 Million in Series A Financing

Breakthrough approach to developing safe and effective therapies for unmet needs in neuropsychiatric disorders Financing will allow Synendos Therapeutics to complete pre-clinical development and progress lead candidate through proof of concept clinical study Supported by strong European investor syndicate co-led by Kurma Partners and Sunstone Life Science Ventures Synendos Therapeutics (Synendos), a biopharmaceutical company developing a new class of small molecules aimed at restoring the
 
5. October 2020

btov Partners, HV Holtzbrinck Ventures and HTGF invest in Real World Evidence and Patient-Reported Outcomes: 5 million euros for heartbeat medical

New standards for care management are set by connecting and utilising clinical data alongside data tracking patient-provided perspectives on their health status over timeFundamental trend in health care: Patient-Reported Outcome Measures (PROMS) and Real World Evidence (RWE)Over 200 hospital teams, registries and research institutions have registered to use the platform registered as a CE-marked medical device The digital health start-up heartbeat medical has closed a Series A financing r